



(51) International Patent Classification:

C07D 519/00 (2006.01) *A61K 31/55* (2006.01)
C07D 487/04 (2006.01) *A61P 31/14* (2006.01)

(21) International Application Number:

PCT/US2013/050640

(22) International Filing Date:

16 July 2013 (16.07.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/672,905 18 July 2012 (18.07.2012) US

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).(72) Inventors: DELMONTE, Albert J.; c/o Bristol-Myers
Squibb Company, 1 Squibb Drive, New Brunswick, New
Jersey 08903 (US). NATALIE, JR., Kenneth J.; 516
Stanton Station Road, Flemington, New Jersey 08822
(US). FRAUNHOFER, Kenneth J.; c/o Bristol-Myers
Squibb Company, 1 Squibb Drive, New Brunswick, New
Jersey 08903 (US). RISATTL, Christina Ann; c/o Bristol-
Myers Squibb Company, 1 Squibb Drive, New Brunswick,
New Jersey 08903 (US). HANG, Chao; c/o Bristol-Myers
Squibb Company, 1 Squibb Drive, New Brunswick, New
Jersey 08903 (US). GAO, Zhinong; 18 Wilkinson Way,
Princeton, New Jersey 08540 (US). DAVULCU, Akin H.;
c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New
Brunswick, New Jersey 08903 (US). HU, Wenhao; 65 Jin-
shajiang Road, Building 54-502, Shanghai 200062 (CN).(74) Agents: EPPERSON, James et al.; Bristol-Myers Squibb
Company, Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: NOVEL METHODS AND INTERMEDIATES FOR THE PREPARATION OF (4BS,5AR)-12-CYCLOHEXYL-N-(N,N-DIMETHYL-SULFAMOYL)-3-METHOXY-5A-((1 R,5S) -3-METHYL-3,8-DIAZABICYCLO[3.2.1]OCTANE-8-CARBONYL)-4B,5,5A,6-TETRAHYDROBENZO [3,4]CYCLOPROPA[5,6]AZEPINO[1,2-A]INDOLE-9-CARBOXAMIDE

(57) Abstract: The present invention provides methods and intermediates for the preparation of (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide (formula I), including pharmaceutically acceptable salts. The compound has activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

